MedicalPhant · An advanced 3D simulator to generate 3D-personalized tissue and organ models for diagnosis, planning and pre-treatment of medical vascular interventions

VALIDA INNOVATION S.L. emerged with the goal of developing a new 3D simulator that improves the diagnosis, planning and pre-treatment interventions and therefore, improving patient safety and reduction of associated cost to medical errors. This simulator provides a high value in 3D organ models due to its physical mechanical identical to the real ones are able to replicate the patient´s own organ and pathology. The main objective of MedicalPhant project is to develop and commercialized, based on MRI, ECO and CAT studies on patients, a cardiovascular personalized model of external and internal vasculature that allows simulating complex clinical situations due to cardiovascular diseases are the main cause of death globally. Currently, the simulator prototype has a technology level TRL6 and it has been validated in a relevant environment through its implementation in a real case study of cardiovascular surgery providing diagnostic capacity before intervention and patient´s safety after intervention. However, the company needs to work in the implementation of the business model, in the industrial adaptation of our prototype and, in achieving the certification of our 3D simulator to be commercialized. The key stakeholders involved in this project will be hospitals to carry out clinical trials, private, public hospitals and universities to use our technology, specialized organizations in charge of certificating our device to obtain the CE Mark and FDA, key opinion leaders to get a better penetration on the market and patient associations which will contribute to the dissemination of our innovative 3D printing technology in the cardiovascular market. The initial plan to commercialize the MedicalPhant consists in the combination of own production with a partner plus licensing of the technology. According to our estimation, the cumulative cash flow projected by VALIDA INNOVATION at year 5 will amount €10.3M meaning a ROI of 2.6%.